Novo Nordisk’s weight loss drugs Ozempic and Wegovy transformed the firm into a global pharmaceutical giant.
But four years after Wegovy’s US launch, the Danish drugmaker’s market value has plummeted.
@sanne_wass explains why http://bloom.bg/4lWJtL8
Novo’s copycat problem wasn’t supposed to last this long. It began when the company was unable to meet customer demand for its weight-loss drugs in the US, clearing the way for compounding pharmacies to step in. These pharmacies are allowed to make and sell cheaper copies of a medicine when brand-name drugs are in short supply, and their products don’t go have to go through the same rigorous approval process.
